Tenaya Therapeutics Inc (NASDAQ: TNYA)’s stock price has plunge by -1.00relation to previous closing price of 1.50. Nevertheless, the company has seen a -2.30% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-13 that Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Additional Cohort 1 Data to be Reported in 1H25 Building on Promising Initial Data Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today provided an update on its clinical development programs and outlined its strategic priorities for 2025.
Is It Worth Investing in Tenaya Therapeutics Inc (NASDAQ: TNYA) Right Now?
Additionally, the 36-month beta value for TNYA is 2.89. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TNYA is 65.64M and currently, short sellers hold a 18.92% ratio of that float. The average trading volume of TNYA on January 14, 2025 was 4.94M shares.
TNYA’s Market Performance
TNYA’s stock has seen a -2.30% decrease for the week, with a -59.43% drop in the past month and a -16.10% fall in the past quarter. The volatility ratio for the week is 8.63%, and the volatility levels for the past 30 days are at 17.33% for Tenaya Therapeutics Inc The simple moving average for the past 20 days is -8.35% for TNYA’s stock, with a -50.61% simple moving average for the past 200 days.
Analysts’ Opinion of TNYA
Leerink Partners, on the other hand, stated in their research note that they expect to see TNYA reach a price target of $7. The rating they have provided for TNYA stocks is “Outperform” according to the report published on November 30th, 2023.
H.C. Wainwright gave a rating of “Buy” to TNYA, setting the target price at $25 in the report published on June 15th of the previous year.
TNYA Trading at -35.14% from the 50-Day Moving Average
After a stumble in the market that brought TNYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.82% of loss for the given period.
Volatility was left at 17.33%, however, over the last 30 days, the volatility rate increased by 8.63%, as shares sank -46.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.78% lower at present.
During the last 5 trading sessions, TNYA fell by -3.95%, which changed the moving average for the period of 200-days by -71.71% in comparison to the 20-day moving average, which settled at $1.6190. In addition, Tenaya Therapeutics Inc saw 3.85% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNYA starting from Saito Chihiro, who sale 2,258 shares at the price of $2.12 back on Nov 18 ’24. After this action, Saito Chihiro now owns 60,983 shares of Tenaya Therapeutics Inc, valued at $4,787 using the latest closing price.
Saito Chihiro, the SVP, Accounting and Fin. Ops. of Tenaya Therapeutics Inc, sale 2,363 shares at $2.89 during a trade that took place back on Aug 16 ’24, which means that Saito Chihiro is holding 63,241 shares at $6,840 based on the most recent closing price.
Stock Fundamentals for TNYA
Current profitability levels for the company are sitting at:
- -6.95 for the present operating margin
- 0.59 for the gross margin
The net margin for Tenaya Therapeutics Inc stands at -6.64. The total capital return value is set at -0.99. Equity return is now at value -84.49, with -70.20 for asset returns.
Based on Tenaya Therapeutics Inc (TNYA), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -6.47.
Currently, EBITDA for the company is -122.51 million with net debt to EBITDA at -0.06. When we switch over and look at the enterprise to sales, we see a ratio of 7.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.27.
Conclusion
In conclusion, Tenaya Therapeutics Inc (TNYA) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
